Abstracts tagged "Adalimumab"

Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Daniel Groth¹, Sivia Lapidus², Simona Nativ² and Maria Perez³, ¹Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Jennifer Rammel¹, Patricia Rosillo¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
Abstract Number: 45 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Clinic, Sankt Augustin, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 92 • 2016 ACR/ARHP Annual Meeting
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?
Einav Srulovici^1,2, Vishvas Garg³, Adi Ghilai², Becca Feldman², Moshe Hoshen², Ran Balicer², Martha Skup⁴ and Maya Leventer-Roberts², ¹School of Nursing, University of Haifa, Haifa, Israel, ²Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In Israel, patients treated with adalimumab (ADA) can enroll in a patient support program (PSP) provided by AbbVie, which includes a home visit by…
Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis
Joachim Sieper¹, Atul A. Deodhar², Maja Hojnik³, Ying Zhang⁴ and Maxime Dougados⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Oregon Health and Science University, Portland, OR, ³AbbVie, Ljubljana, Slovenia, ⁴AbbVie, North Chicago, IL, ⁵René Descartes University and Hôpital Cochin, Paris, France
Background/Purpose: Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…
Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Dao Xuan Nguyen, Centre of Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Bohdan P. Harvey¹, Chenqi Hu², Dongdong Wang², Yu Tian² and Zehra Kaymakcalan¹, ¹Global Biologics, AbbVie Bioresearch Center, Worcester, MA, ²DMPK-BA, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…
Abstract Number: 2639 • 2016 ACR/ARHP Annual Meeting
Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Shintaro Hirata¹, Xingbin Wang², CC Hwang³, Ippei Miyagawa⁴, Satoshi Kubo¹, Kazuhisa Nakano⁵, Shingo Nakayamada⁵, Kazuyoshi Saito⁴, Nadine A. Defranoux² and Yoshiya Tanaka⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: The multi-biomarker disease activity (MBDA) (Vectra® DA) score has been reported to predict disease relapses in patients with rheumatoid arthritis (RA) in sustained remission…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 1245 • 2016 ACR/ARHP Annual Meeting
Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective
Jeffrey D. Greenberg¹, Efthalia Nikoglou², Praveen Gunda³, Jacqueline Palmer⁴ and Steffen Jugl⁵, ¹Corrona, LLC, Southborough, MA, ²Novartis Ireland, Ltd, Dublin, Ireland, ³Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Comparison of Secukinumab vs Adalimumab in a cost per responder analysis based on a matching-adjusted indirect comparison of efficacy data for the treatment of psoriatic…
Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Carlos Fernández-Díaz¹, Ricardo Blanco¹, Vanesa Calvo-Río¹, Javier Loricera¹, J. Sanchez-bursón², Norberto Ortego Centeno³, Jose L. García Serrano⁴, Miguel Cordero⁵, J. Vazquez⁶, Emma Beltran⁷, Elia Valls⁸, O. Maiz Alonso⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, Angel García-Aparicio¹², F.j Toyos-saénz¹³, L. Martinez-Costa¹⁴, Lucia C. Domínguez-Casas¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Valme, Hospital Valme, Sevilla, Spain, ³Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ⁵Ophthalmology, Hospital de León, León, Spain, ⁶Rheumatology, Hospital de Ferrol, Ferrol, Spain, ⁷Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁹Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹⁰Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ¹¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹²Rheumatology, Ophthalmology and rheumatology, Hospital de Ferrol, Ferrol, Ferrol, Spain, ¹³Rheumatology,, Hospital Virgen de la Macarena, Sevilla, Spain, ¹⁴Hospital Dr. Peset., Valencia, Spain
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…
Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Ivan Foeldvari¹, Nicolino Ruperto¹, Daniel J Lovell², Gerd Horneff¹, Hans-Iko Huppertz³, Pierre Quartier⁴, Gabriele Simonini¹, Mareike Bereswill⁵, Jasmina Kalabic⁵, Alberto Martini¹ and Hermine I. Brunner², ¹PRINTO-IRCCS, Genova, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO-IRCCS, Genoa, Italy, ⁴Hôpital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting
Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Lucia Cristina Domínguez-Casas¹, Vanesa Calvo-Río¹, Ricardo Blanco², Carlos Fernández-Díaz¹, Paz Rodríguez-Cundín³, Emma Beltran⁴, Marisa Hernández-Garfella⁵, Jose M Herreras⁶, Miguel Cordero-Coma⁷, Marina Mesquida⁸, Alfredo Adan⁹, M. Victoria Hernández¹⁰, David Diaz-Valle¹¹, Ignacio Torre-Salaberri¹², Manuel Díaz-Llopis¹³, Roberto Gallego¹⁴, Olga Maiz-Alonso¹⁵, Santos Insua¹⁶, Félix Francisco¹⁷, Raquel Almodóvar González¹⁸, Oscar Ruiz Moreno¹⁹, Fernando Jiménez-Zorzo²⁰, Javier Manero²¹, Myriam Gandía²², Joan Miquel Nolla²³, Nuria Vegas-Revenga²⁴, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Ophthalmology, Hospital de León, León, Spain, ⁸Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁹Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ¹⁰Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ¹¹Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹³Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophtalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital Universitario Donostia, Donostia, Spain, ¹⁶Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ¹⁷Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁹Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ²⁰Hospital Miguel Servet, Zaragoza, Spain, ²¹Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²²Rheumatology, Hospital Puerta del Mar, Cadiz, Spain, ²³Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].